Marksans Pharma Ltd Share Price Target – 2024, 2025, 2030, 2040 | Marksans Pharma Ltd Share Price Target – 2026
Written by – Parth Jayswal
Introduction
- The Indian Pharma sector has achieved 3rd rank in terms of trading volume. In terms of valuation, it has ranked 13th biggest pharma sector at the global level. The pharma industry has achieved popularity for generic medicines and producing vaccines at low cost. In FY-24, the Indian pharma sector made a contribution of USD 27.85 billion in drugs and pharma exports. The Indian pharma companies are not limited to exports but is the top leader in APIs and formulations. The pharma sector makes a contribution of 57% of API to the list which is verified by WHO. As per the latest amendments in policy and rules made by government in this sector has placed India as the top market for investments at the global level and provide support by developing manufacturing plants.
- For making foreign investments in India, the Indian pharma sector is one of the top 10 interesting industries for investment purpose. The 100% of FDI will be allocated for greenfield projects and 74% of FDI will go towards brownfield projects under automation path, the government has made announcement for setting up 3 huge drug parks and PLI scheme of up to Rs 6940 crores that has been permitted for marketing of domestic production of Drug Intermediaries and Active Pharmaceutical Ingredients in India. The Pharma sector has observed 8% growth in Q4 of 2023. In FY-24, the Indian Pharma sector is forecasted to reach $65 billion by end of 2024 and it is projected to hit $130 billion by 2030. The pharma industry is rapidly adopting modern technology, the industry has observed huge changes in past years and is forecasted to increase at 22.4% CAGR in the future. The pharma sector has observed faster growth, the government has contributed to support approximately 2000 startups. Taking inspiration from this, the large pharma companies will make a contribution of 5 to 10% of company’s revenues for R&D purpose for biotech startups with a purpose that it will grab attention of global partners.
- The OTC products at global level includes following categories such as pain relievers, cough, vitamins, eye care products, pain relievers, cough, cold and flu, and weight loss. The cough, cold, and flu market will observe rapid growth in next few years, as population will increase in future and people will suffer disease which will lead to a rise in demand for OTC products. The OTC drug market is $137 billion in 2024 and is projected to increase $163 billion by 2029. The OTC market is projected to rise by 3.51% CAGR between 2024 to 2029. In this article, you will learn interesting information about Marksans’s pharma share price target, promoter, market cap, revenue, sales, net profit, loan taken by company, and shareholding pattern.
Marksans Pharma Ltd – Key Points
| Name of the promoter | Mark Saldanha |
| Industry | Pharmaceutical |
| Established | 2001 |
| Industry Experience | 23 years |
| Headquarters | Mumbai, India |
| Products | 300+ |
| Employees | 2000+ |
Marksans Pharma Ltd – Statistics
| Market cap | Rs 13,133 crores |
| ROCE | 20.6% |
| ROE | 16.5% |
| products in pipeline | 70+ |
| Book value | Rs 45.6 |
| Face value | Rs 1.00 |
| All-time high/low | Rs 329/97.4 |
About Marksans Pharma Ltd
- The company has over 300 products in portfolio, the company pays attention on OTC and prescription based medicines applied in upper respiratory, CVS, pain management, CNS Oncology, antibiotics, digestives, antidiabetic. Taking benefiut of our modern manufacturing machines and strict compliance of cGMP rules, the company consistently provides best quality products that follow international regulatory rules and guidelines.
- The business model of company is integrated with 4 manufacturing plants located in UK, India, Goa, Uk and 4 R&D centres in Navi Mumbai, Goa, USA, and UK and strong team of employees. The full aim of company is to provide Quality Assurance (QA) and Quality Control (QC) has supported us to stand unique in the market where company operates. The company has specific production of generic medicines and coompany pays attention on Quality Assurance (QA) and Quality Control (QC) has encouraged company to stay ahead in competition.
- The company has diversified product portfolio of tablets (enteric coated, plain, and film coated), soft gelatin capsules, fungal infection ointments, oral liquid. The company has largest manufacturing plant of soft gelatin capsules approved by TGA, MHRA, FDA. The company has portfolios of 300 products and 1500 SKUs. The company exports its medicines in regulated markets such as Canada, UK, USA, Europe, Australia. The company is increasing its manufacturing capacity to produce 26 billion tablets and capsules annually. The company is focused on fulfilling requirements of customer and ther performance of company in international market is led by strong R&D infrastructure, robust product pipeline, high operating efficiencies, fast launching of products, and maintained gains in market share. In past few years, the company has gained command in highly controlled markets, having expertise in OTC and prescription based medicines.
- The company has setup best class formulation manufacturing units in India, UK and USA. The manufacturing plants located in Goa, India has over 43,325 sq meter and is integrated with modern infrastructure, automated manufacturing and packaging lines and amazing unique innovation of products and building formulation processes to meet the international guidelines. The company has a strong R&D infrastructure which includes dedicated R&D centres in Goa and Navi Mumbai, India. There are more than 300+ product portfolio in different categories such as anti-diabetic, central nervous system, pain management, upper respiratory, gastrointestinal medicines.
- The company has strong manufacturing units, wide range of products, and pays attention to controlled markets. The company is working on forward integration along with robust R&D is projected to develop our competition and manage a stable distribution network of innovative products.
- There are two subsidiaries in UK through which company undertakes its operations, Bell, Sons & Co. Limited and Relonchem Limited. The company has build strong presence in European market and developed its positions as top 5 Indian companies in UK.
- There are two subsidiaries of Marksans Pharma:
- Bell’s Healthcare ( OTC portfolio) – The company has achieved expertise in own lable products by supplying to retail shops, wholesalers, distributors, super markets. The company provides wide variety of medicines such as pain relief, upper respiratory, skincare products, ear care, gastrointestinal treatments.
- Relonchem (High end Rx portfolio) – The company has licenses of over 160 products and delivers own brand pharma medicines. The company has huge variety of medicines including anti-diabetic, allergy treatments, antiviral medications, anticancers, CNS orders, pain relief.
- The company has collaborated with main retailers in UK such as Lloyds, NHS, ASDA, AAH, Boots-Almus, Morrisons and Coop to market its products. The company has strong suuply in retail chains, wholesalers, supermarkets.
- In next 3 years, the company is planning to start 34 new filings. At present, there are 16 products whose approval is pending which shows that there is stable increment in products.
- In USA, the company produces solid does generic medicines and sells finishd products in sealed packed products through our subsidiary, Time Cap laboratories Inc. (TCL). TCL has expertise in producing sustainbed and delayed release dosages. The company also manufactures huge variety of solid oral dosage forms which includes, hard gelatin capsules, tablets. The exhaustive range of upper respiratory medicines, dietary supplements, analgestics and prescription based medicnes are also produced by TCL.
- The production of TCL is certified by Good Manufacturing Practices (GMP) which assures strict legal compliance and best quality standards at worldwide level. The company is highly experienced in developing best quality products fulfilling to both OTC and Rx markets across in following segments such as cardiac, CNS, gastro-intestinal, pain management, upper respiratory. The company sells its products through big pharmacies and wholesalers in US. The retail clients of comapnies are Walmart, Dollor General, CVS, Walgreens, Target and Kroger are some large clients in retail segment.
- At present, the company has 32 products in its portfolio which includes 20 oral solids and softgels and 12 creams, liquids, ointments. The company has strong list of products with best quality and investment in R&D is increased. Time Cap Labs Inc. has maintained well presence in US market. The company has established strong presence in pharma sector in New Zealand and Australia. Out of total revenue received by company these markets contribute 3rd largest share in revenue. The company has entered into partnership with Australia’s largest retailers and pharmacies to scale its distribution channel. Nova is also involved in distribution of its products to majaor medical stores in Australia, improving company’s reach and deeper penetration in market.
- New Zealand, australia, and remaining countries contribute 12% of total revenue generated. This emphasizes importance of New Zealand and Australian markets in overall performance of company.
- Marksans Pharma will launch 10 new products in upcoming 2 years Australia and New Zealand. The purpose of company is to build strong presence in New Zealand and Australia by focusing on improving product and increasing its network. The company has expanded its geographical distribution in Africa, South East Asia, Middle East, and CIS countries. The Rest of the World (RoW) sector includes 10 countries, spanning MENA and CIS areas. The RoW market is very crucial for company as they contribute specific portion to overall business of company. At present, there are 124 products available for sale in RoW markets.
- There are 120 products whose approval is pending in RoW markets, which shows that our effort is consistent and distribution in market. Moreover, the company has 108 products in basket for launching in future. The RoW segment shows amazing growth for increasing sales and market improvement.
Marksans Pharma Ltd – Revenue & Net profit
| Particulars | Fy-24 (In crores) |
|---|---|
| Sales | 2,177 |
| Expenses | 1,719 |
| Other income | 50 |
| Interest | 11 |
| Depreciation | 74 |
| Profit before tax | 424 |
| -Tax (%) | (26%) |
| Net Profit | 315 |
| EPS in Rs. | 6.92 |
Shareholding pattern
| Promoters | 43.85% |
| FIIs | 15.57% |
| DIIs | 5.17% |
| Public | 35.40% |
Marksans Pharma Ltd – Watch Full Video
Disclaimer – Stock market is a highly volatile market and unstable. Do your proper research and study before investing. Our website aims to provide information regarding the stock market. We are not responsible if you suffer any loss. Spend enough time on research. We are not providing investment or financial advice.
Marksans Pharma Ltd Share Price Target – 2024 to 2040
| Year | Minimum price (Rs.) | Average price (Rs.) | Maximum price (Rs.) |
|---|---|---|---|
| 2024 | 289 | 315 | 340 |
| 2025 | 343 | 373 | 402 |
| 2026 | 408 | 449 | 498 |
| 2027 | 505 | 574 | 642 |
| 2028 | 647 | 729 | 810 |
| 2029 | 815 | 897 | 978 |
| 2030 | 995 | 1015 | 1034 |
| 2040 | 4978 | 5034 | 5090 |
Marksans Pharma Ltd Share Price Target – 2024
- If market faces bearish sentiments, the minimum projected price is anticipated to hit Rs 289. The average trading price is projected to hit Rs 315 at the end of the year. If market observes bullish sentiments, the maximum forecasted price is projected to hit Rs 340. Marksans Pharma has scaled its distribution channel in US market by acquiring Time-Cap Labs (TCL), a company which has expertise in producing solid-dose generic medicines. This smart acquisition has allowed the company to capitalise in rising needs within the market sector. Taking benefit of TCL’s production capacity, the company has smartly entered into rising needs of pharma industry of US pharma industry by selling finished products in sealed packed quantities.
Marksans Pharma Ltd Share Price Target – 2025
- If market faces bearish sentiments, the minimum forecasted price is anticipated to reach Rs 343. The average trading price is projected to hit Rs 373 at the end of the year. If market observes bullish sentiments, the maximum projected price is estimated to reach Rs 402. The formulation business of company is doing well which has resulted in growth in US and North American regions. Between 2017 to 2024, this sector observed notable increment of 18.5% and its revenue hit Rs 918 crores. Marksans Pharma has managed its position as one of the pioneer Indian companies in this area with support of its two subsidiaries Bell, Sons and Co. Limited which has expertise in providing best quality products in diufferent segments such as pain relief, anti-cancer, anti-diabetic, skin care, anti-ulcerative, anti-depressant.
Marksans Pharma Ltd Share Price Target – 2026
- If market observes bearish sentiments, the minimum projected price is anticipated to touch Rs 408. The average trading price is projected to hit Rs 449 at the end of the year. If market observes bullish sentiments, the maximum projected price is estimated to reach Rs 498. In FY-2005, Marksans acquired Nova Pharma Australasia Pvt. Ltd by stepping into Australian markets. At present, they develop third largest portion of revenue. With the help of Nova, Marksans has attained around 100 Marketing Authorisations (MA) and appeared as major supplier of generic medicines. The company has wide variety of diversified products. The success achieved by Marksan’s is integrated in its strong commitment and systematic growth. The company is successfully grabbing the OTC market of multi-billion dollar achieving growth of 17% CAGR.
Marksans Pharma Ltd Share Price Target – 2027
- If market faces bearish sentiments, the minimum projected price is anticipated to hit Rs 505. The average trading price is forecasted to hit Rs 574 at the end of the year. If market observes bullish signals, the maximum forecasted price is anticipated to touch Rs 642. The company has build strong presence in OTC market this is possible due to deep expertise in manufacturing and delivering best quality products to retail shops, by developing strong position as a cost-efficient and to improve margin. The company has actively taken steps to crack challenges of supply chain and increase our delivery time. The company has improved its operational capacity by adding 200 fresh employees at our plant to expand our business. The company has made huge investment in developing team and build best infrastructure to become market leader.
Marksans Pharma Ltd Share Price Target – 2028
- If market observes downward trends, the minimum projected price is anticipated to hit Rs 647. The average trading price is projected to hit Rs 729 at the end of the year. If market observes bullish sentiments, the maximum forecasted price is anticipated to hit Rs 810. The company has made a strong commitment to shift towards forward integration initiatives to further increase profit margins and safeguard front-end capabilities and architecture. The company focuses on acquisitions which helps to grow their business. The main strategy of the company is to acquire well-set-up companies in distribution markets and the EU to push entry into market. The balance sheet of the company is very fundamentally very strong which supports us to enter into smart acquisitions and scale the business.
Marksans Pharma Ltd Share Price Target – 2029
- If market faces bearish sentiments, the minimum projected price is anticipated to reach Rs 815. The average trading price is projected to hit Rs 897 at the end of the year. If market observes bullish sentiments, the maximum forecasted price is expected to touch Rs 978. The company has increased stock of raw materials in US warehouses to fulfill the production requirements and shortages. This has resulted in increase in stock reserves, it is a crucial step to protect against supply chain uncertainties and manage operations. The company enters into collaboration with contract manufacturing organizations to assure proper margin is achieved. It encourages us to fulfill the requirement of innovation, increases turnaround time to bring solutions in the market.
Marksans Pharma Ltd Share Price Target – 2030
- If market observes bearish sentiments, the minimum projected price is anticipated to hit Rs 995. The average trading price is projected to hit Rs 1015 at the end of the year. If market observes bullish sentiments, the maximum projected price is anticipated to touch Rs 1034. The company gets the benefit of state-of-the-art infrastructure to become a distribution partner in regulated markets. The company is very focused on developing IP assets, especially in the specific segment. Additionally, the company is building strong presence in OTC sector among regulated markets. The company is also investing in manufacturing plants to maintain proper cost and manage a health product distribution.
Marksans Pharma Ltd Share Price Target – 2040
- If market faces bearish sentiments, the minimum forecasted price is expected to hit Rs 4978. The average trading price is projected to hit Rs 5034 at the end of the year. If market observes bullish sentiments, the maximum projected price is expected to reach Rs 5090. The company has crossed its revenue forecasts and attained permission from USFDA and authorities from UK MHRA for products in respiratory, and pain management. Moreover, the manufacturing plant at the Tevapharm unit is going as per our planning. These achievements show robust implementation of operations and strategic foresight. The company has strong commitment to increase market share and develop a strong channel of products.
FAQs
Q1) Who is the owner of Marksans Pharma Ltd?
- Ans – The promoter and founder of company is Mark Saldanha.
Q2) Is Marksans Pharma Ltd a debt free company?
- Ans – No, Marksan’s Pharma is not a debt-free company. The Long-term borrowing of company is nil. The short-term borrowing of company for FY-24 is Rs 29 crores and the net profit of company is Rs 315 crores.
Q3) What does Marksans Pharma Ltd do?
- Ans – The company is engaged in production of OTC products and medicines such as pain killer, diabetes, anti-biotics, and oncology. The company has portfolio of 300 products.
Q4) What is turnover of Marksan’s Pharma Ltd?
- Ans – The turnover of the company for FY-24 is Rs 2,177 crores which has shown growth of 17.55% compared to FY-23 where turnover was Rs 1,852 crores.
Q5) Is Marksan’s Pharma Ltd company good for long-term investment?
- Ans – Yes, Marksan’s Pharma is good company for long-term investment. The company has shown consistent growth in sales from 2013 to 2024 i.e. from Rs 438 crores to 2,177 crores. The net profit of the company was Rs 49 crores in FY-13 which was increased to Rs 315 crores in FY-24.
Q6) Where is the Marksan’s Pharma headquarters situated?
- Ans – The headquarters of Marksan’s Pharma is situated in Mumbai city, India.
Q7) Is Marksan’s Pharma Ltd multibagger share?
- Ans – Yes, Marksan’s Pharma Ltd is a multi-bagger share. The share price of the company in 2019 was Rs 12.75 which has shown growth of 2173.73% and reached to Rs 289 in 2024. The company has achieved exponential growth in sales from Rs 1000 crores in FY-19 to Rs 2,177 crores in FY-24.
Read other Articles